Botulinum Toxin Therapy in Hidradenitis Suppurativa

Launched by UNIVERSITY OF MASSACHUSETTS, WORCESTER · May 31, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment for a skin condition called hidradenitis suppurativa (HS), which causes painful lumps and inflammation. Researchers want to see if using botulinum toxin, a substance known for reducing muscle activity, can help lower inflammation in people with HS. The hope is that by blocking certain signals in the body, this treatment can improve skin lesions and reduce discomfort.

To join the study, participants need to be adults aged 18 to 75 who have been diagnosed with HS for at least a year and have lesions in two or more areas of their body. Unfortunately, some people won't be eligible, such as those with certain medical conditions, infections, or who are pregnant or breastfeeding. If you participate, you can expect to receive the treatment and be monitored for its effects on your condition. This study is currently recruiting, and your involvement could help improve understanding and treatment options for HS in the future.

Gender

ALL

Eligibility criteria

• Inclusion:
• • Adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (HS)
• • HS skin lesions of duration at least 1 year, HS skin lesions in at least two different body areas
• Exclusion:
• • Age \< 18 years or \> 75 years
• • pregnant or breastfeeding
• • neuromuscular disorder (ex. ALS, myasthenia gravis, Lambert-Eaton syndrome, myopathy)
• • medical co-morbidity that is a relative contraindication to skin biopsy procedure (ex. end stage congestive heart failure or coagulopathy)
• • active bacterial, fungal, or viral infection in the treatment area
• • known hypersensitivity to botulinum toxin A preparations or any of their components (human albumin, saline, lactose, sodium succinate)
• • prisoners
• • adults unable to consent for themselves.